Assessing the Broader Economic Impact of Investment in Healthcare Interventions—How Input-Output Modeling Complements HTA
Moderator
Malina Müller, BA, MA, PhD, WifOR Institute, Darmstadt, Germany
Speakers
Karam Diaby, BSc, MSc, PhD, Otsuka, Princeton, NJ, United States; Amit Kulkarni, Otsuka, Princeton, NJ, United States; Billy Leung, MA, REMI, Amherst, MA, United States
Presentation Documents
ISSUE: Recently, discussions about health investments focus on immediate costs, overlooking the connectedness with economic growth. We present and discuss opportunities to integrate macroeconomic viewpoints in traditional evaluation to address the repercussions of capital injection into the health sector. The panel underscores the need for innovative analytical concepts and confers about their applicability from different perspectives. OVERVIEW: M.M. introduces the topic sharing impressions from conversations with health ministries and the G20 Health and Development Partnership about systematic measurement of value creation through health investments(10min). The presenters emphasize different viewpoints(30min). D.G. explains how broader value analysis supports ISPOR Latin America Consortium and promotes action of FIFARMA to enable equal access to medicines for all patients regardless their socioeconomic conditions. B.L. shares his extensive experience in Input/Output modelling, presenting recent research across 51 US regions. He assesses state level health industry effects: the economic footprint of the pharmaceutical industry and its supply chains and further health impacts (improved survival and reduced sick time) that translate into a healthier, more productive workforce, and improve social and economic outcomes. V.D. provides insights on value assessment of investment in Alzheimer treatment in the US. He systematically integrates Input/Output modelling in traditional HTA and illustrates the political relevance of broader economic value quantification. Following this, the speakers will be interviewed about their key messages and debate about challenges and limitations of the introduced concepts(10min). We close with an interactive discussion with the audience(10min). This panel provides valuable insights for researchers, pharmaceutical industry stakeholders, and decision makers on how novel evidence-based strategies could be utilized to align health investments with national and regional development goals.
Code
111
Topic
Economic Evaluation, Health Policy & Regulatory, Study Approaches